A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)

Trial Profile

A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Terbinafine (Primary)
  • Indications Onychomycosis
  • Focus Therapeutic Use
  • Sponsors Moberg Pharma
  • Most Recent Events

    • 08 Aug 2017 According to a Moberg Pharma media release, enrolment for two phase 3 studies of MOB-015 has taken longer than expected and the company have taken a number of measures to speed up the process and are now on the right track, however enrolment will likely not be completed this year with somewhat higher costs as a result.
    • 28 Sep 2016 According to Moberg Pharma media release, this study is designed to support registration in North America, Europe and other major markets.
    • 28 Sep 2016 According to Moberg Pharma media release, patient enrollment has started in U.S., Canada and Germany.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top